NEW YORK – Natera and Personalis said on Wednesday that they are partnering on cancer treatment monitoring and molecular residual disease (MRD) testing.
Under the non-exclusive agreement, Natera will use matched tumor and normal exome sequencing data generated by Personalis to validate the design of its Signatera personalized circulating tumor DNA assays. The deal covers MRD testing for both clinical and research use and Natera will be responsible for commercializing the assays.